Literature DB >> 31783178

Anaplastic Lymphoma Kinase Gene Rearrangement in Children and Young Adults With Mesothelioma.

Idrees Mian1, Zied Abdullaev2, Betsy Morrow1, Rosandra N Kaplan3, Shaojian Gao1, Markku Miettinen2, David S Schrump4, Valerie Zgonc2, Jun S Wei5, Javed Khan5, Svetlana Pack2, Raffit Hassan6.   

Abstract

INTRODUCTION: Children and young adults diagnosed with malignant mesothelioma may have unique genetic characteristics. In this study, we evaluated for the presence of the anaplastic lymphoma kinase (ALK) translocations in these patients.
METHODS: In a prospective study of mesothelioma natural history (ClinicalTrials.gov number NCT01950572), we assessed for the presence of the ALK translocation in patients younger than 40 years, irrespective of the site of disease. The presence of this translocation was assessed by means of fluorescence in situ hybridization (FISH). If the patients tested positive for the ALK translocation, both immunohistochemistry and RNA sequencing were performed on the tumor specimen.
RESULTS: Between September 2013 and December 2018, 373 patients were enrolled in the mesothelioma natural history study, of which 32 patients were 40 years old or younger at the time of their mesothelioma diagnosis. There were 25 patients with peritoneal mesothelioma, five with pleural mesothelioma, one with pericardial mesothelioma, and one with bicompartmental mesothelioma. Presence of an ALK translocation by FISH was seen in two of the 32 patients (6%) with mesothelioma. Both patients, a 14-year-old female and a 27-year-old male, had peritoneal mesothelioma and had no history of asbestos exposure, prior radiation therapy, or predisposing germline mutations. Neither had detectable ALK expression by immunohistochemistry. RNA sequencing revealed the presence of an STRN fusion partner in the female patient but failed to identify any fusion protein in the male patient.
CONCLUSIONS: Young patients with peritoneal mesothelioma should be evaluated for the presence of ALK translocations. Presence of this translocation should be assessed by FISH and these patients could potentially benefit from tyrosine kinase inhibitors targeting ALK. Published by Elsevier Inc.

Entities:  

Keywords:  ALK mutation; FISH testing; Mesothelioma; Peritoneal mesothelioma; Targeted therapy; Young patients

Year:  2019        PMID: 31783178      PMCID: PMC7044061          DOI: 10.1016/j.jtho.2019.11.011

Source DB:  PubMed          Journal:  J Thorac Oncol        ISSN: 1556-0864            Impact factor:   15.609


  14 in total

1.  Anaplastic lymphoma kinase (ALK) translocation in paediatric malignant peritoneal mesothelioma: a case report of novel ALK-related tumour spectrum.

Authors:  Kongsak Loharamtaweethong; Napaporn Puripat; Nadda Aoonjai; Apisada Sutepvarnon; Chanyoot Bandidwattanawong
Journal:  Histopathology       Date:  2015-09-02       Impact factor: 5.087

2.  Inherited predisposition to malignant mesothelioma and overall survival following platinum chemotherapy.

Authors:  Raffit Hassan; Betsy Morrow; Anish Thomas; Tom Walsh; Ming K Lee; Suleyman Gulsuner; Meghana Gadiraju; Vasiliki Panou; Shaojian Gao; Idrees Mian; Javed Khan; Mark Raffeld; Snehal Patel; Liqiang Xi; Jun S Wei; Mary Hesdorffer; Jingli Zhang; Kathleen Calzone; Arpita Desai; Emerson Padiernos; Christine Alewine; David S Schrump; Seth M Steinberg; Hedy L Kindler; Mary-Claire King; Jane E Churpek
Journal:  Proc Natl Acad Sci U S A       Date:  2019-04-11       Impact factor: 11.205

3.  Alectinib versus Crizotinib in Untreated ALK-Positive Non-Small-Cell Lung Cancer.

Authors:  Solange Peters; D Ross Camidge; Alice T Shaw; Shirish Gadgeel; Jin S Ahn; Dong-Wan Kim; Sai-Hong I Ou; Maurice Pérol; Rafal Dziadziuszko; Rafael Rosell; Ali Zeaiter; Emmanuel Mitry; Sophie Golding; Bogdana Balas; Johannes Noe; Peter N Morcos; Tony Mok
Journal:  N Engl J Med       Date:  2017-06-06       Impact factor: 91.245

4.  Status of Anaplastic Lymphoma Kinase (ALK) in malignant mesothelioma.

Authors:  Serena Varesano; Claudio Leo; Simona Boccardo; Sandra Salvi; Mauro Truini; Paola Ferro; Franco Fedeli; Pier Aldo Canessa; Paolo Dessanti; Maria Pia Pistillo; Silvio Roncella
Journal:  Anticancer Res       Date:  2014-05       Impact factor: 2.480

5.  Asbestos-related mesothelioma: factors discriminating between pleural and peritoneal sites.

Authors:  K Browne; W J Smither
Journal:  Br J Ind Med       Date:  1983-05

Review 6.  Mechanistic insight into ALK receptor tyrosine kinase in human cancer biology.

Authors:  Bengt Hallberg; Ruth H Palmer
Journal:  Nat Rev Cancer       Date:  2013-10       Impact factor: 60.716

7.  Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for malignant peritoneal mesothelioma: multi-institutional experience.

Authors:  Tristan D Yan; Marcello Deraco; Dario Baratti; Shigeki Kusamura; Dominique Elias; Olivier Glehen; François N Gilly; Edward A Levine; Perry Shen; Faheez Mohamed; Brendan J Moran; David L Morris; Terence C Chua; Pompiliu Piso; Paul H Sugarbaker
Journal:  J Clin Oncol       Date:  2009-11-16       Impact factor: 44.544

8.  Two Cases of Renal Cell Carcinoma Harboring a Novel STRN-ALK Fusion Gene.

Authors:  Hironori Kusano; Yuki Togashi; Jun Akiba; Fukuko Moriya; Katsuyoshi Baba; Naomi Matsuzaki; Yoshiaki Yuba; Yusuke Shiraishi; Hiroshi Kanamaru; Naoto Kuroda; Seiji Sakata; Kengo Takeuchi; Hirohisa Yano
Journal:  Am J Surg Pathol       Date:  2016-06       Impact factor: 6.394

9.  Malignant Mesothelioma Mortality - United States, 1999-2015.

Authors:  Jacek M Mazurek; Girija Syamlal; John M Wood; Scott A Hendricks; Ainsley Weston
Journal:  MMWR Morb Mortal Wkly Rep       Date:  2017-03-03       Impact factor: 17.586

10.  A subgroup of pleural mesothelioma expresses ALK protein and may be targetable by combined rapamycin and crizotinib therapy.

Authors:  Dina Mönch; Sabine Bode-Erdmann; Jörg Kalla; Jörn Sträter; Carsten Schwänen; Roger Falkenstern-Ge; Siegfried Klumpp; Godehard Friedel; German Ott; Claudia Kalla
Journal:  Oncotarget       Date:  2018-04-17
View more
  6 in total

1.  Molecular characterization of diffuse malignant peritoneal mesothelioma.

Authors:  Yin P Hung; Fei Dong; Matthew Torre; Christopher P Crum; Raphael Bueno; Lucian R Chirieac
Journal:  Mod Pathol       Date:  2020-06-05       Impact factor: 7.842

Review 2.  A Novel Malignant Peritoneal Mesothelioma with STRN Exon 2 and ALK Exon 20: A Case Report and Literature Review.

Authors:  Chiho Miyagawa; Hisamitsu Takaya; Kazuko Sakai; Kazuto Nishio; Maho Konishi; Sachiko Minamiguchi; Toshihide Shimada; Noriomi Matsumura
Journal:  Oncologist       Date:  2021-02-22

Review 3.  Pleural mesothelioma classification-update and challenges.

Authors:  Sanja Dacic
Journal:  Mod Pathol       Date:  2021-08-31       Impact factor: 7.842

4.  Pediatric Mesothelioma With ALK Fusions: A Molecular and Pathologic Study of 5 Cases.

Authors:  Pedram Argani; Derrick W Q Lian; Abbas Agaimy; Markus Metzler; Sara E Wobker; Andres Matoso; Jonathan I Epstein; Yun-Shao Sung; Lei Zhang; Cristina R Antonescu
Journal:  Am J Surg Pathol       Date:  2021-05-01       Impact factor: 6.298

Review 5.  When the Diagnosis of Mesothelioma Challenges Textbooks and Guidelines.

Authors:  Giulio Rossi; Fabio Davoli; Venerino Poletti; Alberto Cavazza; Filippo Lococo
Journal:  J Clin Med       Date:  2021-05-30       Impact factor: 4.241

6.  STRN-ALK Fusion in a Case of Malignant Peritoneal Mesothelioma: Mixed Response to Crizotinib, Mode of Resistance, and Brigatinib Sequential Therapy.

Authors:  Valeria Gerthofer; Alexander Scheiter; Florian Lüke; Felix Keil; Kirsten Utpatel; Laura-Maria-Giovanna Pöhmerer; Johannes Seitz; Christoph Niessen; Atanas Ignatov; Wolfgang Dietmaier; Diego F Calvisi; Matthias Evert; Olaf Ortmann; Stephan Seitz
Journal:  JCO Precis Oncol       Date:  2021-09-16
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.